The Daily Populous Sunday April 19th, 2026 evening edition
Authored by time.com and submitted by newtrex_1523

Revolution Medicines’ results came from a Phase III trial, and Goldsmith says the company plans to submit them to the U.S. Food and Drug Administration (FDA) in a request to approve the drug. Revolution Medicines was also the first cancer company to receive a Commissioner’s National Priority Voucher for a cancer drug, which means the FDA will review the application and provide a decision on an expedited timeline. Actuate’s study is an earlier stage Phase II trial, and the company plans to continue studying and testing the drug in more patients.

Taken together, the results provide much-needed hope for the pancreatic cancer community, which hasn’t had as many options as patients with other types of cancer. Immune-based therapies and personalized treatments based on genetic mutations found in a person's tumor, for example, have not worked well against pancreatic cancer. Despite the seemingly small improvement in survival time, such advances are the first step toward more meaningful benefits for pancreatic cancer patients. Dr. Eileen O'Reilly, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center who was involved with the studies on daraxonrasib, says the encouraging findings about daraxonrasib "hopefully set the stage for building on targeted therapy as a major backbone for the treatment of pancreas cancer, and a key goal now is to build and extend these results in all stages."

Mysterious-Outcome37 on April 19th, 2026 at 18:58 UTC »

Phase 3 trial and promising for pancreatic, colorectal, and some type of lung cancer. People with any KRAS, HRAS, NRAS and HER2 mutation should check out this video that goes a bit more into detail. YouTube

Traditional-Meat-549 on April 19th, 2026 at 16:26 UTC »

Please please! I know three people who had it, two died within a very short time

MichaelCoryAvery on April 19th, 2026 at 11:56 UTC »

This is amazing